Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral dabigatran penetration into vitreous and subretinal fluid in retinal detachment surgery
NL-OMON23085Active, not recruiting
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dabigatran in Proliferative Vitreoretinopathy (PVR), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoints: Dabigatran levels in vitreous or subretinal fluid and Thrombin inhibiting activity in vitreous or subretinal fluid. Started Oct 2014; status: active, not recruiting.
02
Drugs
dabigatran
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NL-OMON23085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23085.